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Abstract
Growth hormone secretion is classically modulated by two hypotha-
lamic hormones, growth hormone-releasing hormone and somatosta-
tin. A third pathway was proposed in the last decade, which involves
the growth hormone secretagogues. Ghrelin is a novel acylated pep-
tide which is produced mainly by the stomach. It is also synthesized in
the hypothalamus and is present in several other tissues. This endog-
enous growth hormone secretagogue was discovered by reverse phar-
macology when a group of synthetic growth hormone-releasing com-
pounds was initially produced, leading to the isolation of an orphan
receptor and, finally, to its endogenous ligand. Ghrelin binds to an
active receptor to increase growth hormone release and food intake. It
is still not known how hypothalamic and circulating ghrelin is in-
volved in the control of growth hormone release. Endogenous ghrelin
might act to amplify the basic pattern of growth hormone secretion,
optimizing somatotroph responsiveness to growth hormone-releasing
hormone. It may activate multiple interdependent intracellular path-
ways at the somatotroph, involving protein kinase C, protein kinase A
and extracellular calcium systems. However, since ghrelin has a
greater ability to release growth hormone in vivo, its main site of
action is the hypothalamus. In the current review we summarize the
available data on the: a) discovery of this peptide, b) mechanisms of
action of growth hormone secretagogues and ghrelin and possible
physiological role on growth hormone modulation, and c) regulation
of growth hormone release in man after intravenous administration of
these peptides.
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Introduction
In 1982, before the identification of growth
hormone-releasing hormone (GHRH), Bow-
ers et al. (1) discovered a new group of
synthetic substances with growth hormone
(GH)-releasing ability (for a review, see Ref.
2). These compounds were developed from
the met-enkephalin molecule by theoretical
conformational energy calculations, com-
puter modelling, peptide chemical modifica-
tions, and studies of biological activity. Ini-
tially these small peptides were able to re-
lease GH weakly. Further chemical modifi-
cations led to the development of more po-
tent compounds, including peptides such as
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GH-releasing peptide-6 (GHRP-6), GHRP-
2, hexarelin, and non-peptides such as MK-
0677, which could be administered orally
(2). In the last decade several studies were
performed with these growth hormone se-
cretagogues (GHS), especially with GHRP-
6, and the results suggested a possible role
for these peptides in GH modulation (3). It
was demonstrated that GHS release GH by
different mechanisms than those stimulated
by GHRH (for reviews, see Refs. 2,3). Fur-
thermore, these peptides act through differ-
ent receptors than those of GHRH, soma-
tostatin or opioid peptides. In 1996, Howard
et al. (4) cloned the GHS receptor (GHS-R),
which was mainly located in the anterior
pituitary and in the brain, both in hypotha-
lamic and non-hypothalamic areas. In 1999,
Kojima et al. (5) discovered the endogenous
ligand for these orphan receptors in the stom-
ach, and this new hormone was designated
ghrelin (from ghre, the Indo-European root
of the word “grow”). Ghrelin is also present
in small amounts in the hypothalamus and
induces GH release in a quite potent manner
(5,6). This peptide is a new member of the
brain-gut peptide family, and is also involved
in the control of appetite, an effect appar-
ently independent of GH release (for re-
views, see Refs. 7,8). Ghrelin might have
other actions, which are currently being in-
vestigated (7,8). The discovery of ghrelin is
an excellent example of reverse pharmacol-
ogy, in which a new hormone was isolated
starting from the chemical synthesis of com-
pounds such as GHS, which then led to the
discovery of the endogenous orphan recep-
tor and finally to the isolation of its natural
ligand.
Growth hormone secretagogue
receptor
In 1996 Howard et al. (4) cloned the
GHS-R, which belongs to the G-protein fam-
ily. It has seven transmembrane-spanning
segments and three intracellular and extra-
cellular loops. There are two subtypes of
receptors, GHS-R1a, which is active, and
GHS-R1b, a shorter isoform, which appar-
ently does not have biological activity (4).
Other subtypes might also exist. The human
GHS-R1a has 366 amino acids and is highly
conserved in evolution. It is located in the
anterior pituitary and in the hypothalamus,
and in other areas of the brain, such as
hippocampus and substantia nigra (4). GHS-
R1a was found in several areas of the hypo-
thalamus, including the arcuate, ventrome-
dial and paraventricular nuclei (2,4). Be-
cause of its location it has been suggested
that GHS-R might modulate biological
rhythms, mood, memory, learning, and ap-
petite (2). In the pituitary GHS-R was de-
tected exclusively in somatotrophs by im-
munocytochemistry (2). In knockout mice
for GHS-R1a ghrelin is unable to increase
GH release or food intake, which indicates
that this type of receptor is involved in both
actions of ghrelin (9). It was also shown that
GHS-R1a is present in other tissues such as
pancreas, heart, adrenal gland, and the thy-
roid (10). It is interesting that GHS-R1b has
a widespread distribution in peripheral tis-
sues but its function is still unknown (10).
As mentioned previously, it is likely that
other receptor subtypes might also exist.
Ghrelin: overview
When different tissue extracts were added
to an experimental system with cells ex-
pressing human GHS-R1a, Kojima et al. (5)
surprisingly found a major increase in intra-
cellular calcium concentrations with the ad-
dition of stomach extracts. These investiga-
tors isolated a 28-amino acid peptide with a
fatty acid chain modification (n-octanoic
acid), in the serine 3 residue. This hydropho-
bic compound, which is the first known
natural bioactive peptide modified by an
acyl acid, was called ghrelin. An intriguing
finding was the lack of structural similarity
between ghrelin and the GHS, such as GHRP-
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6 (5). The post-translational fatty acid chain
modification (n-octanoyl residue) is essen-
tial for some of its biological activity, in-
cluding GH release and appetite stimulation.
Shorter fragments, with the first four to five
residues, but with intact acylated serine, are
also able to activate signal transduction of
GHS-R1a in vitro (7). Non-acylated ghrelin,
which is the main circulating form, might
have non-endocrine actions (5). This latter
peptide is mainly secreted from the stomach
as its circulating levels are reduced by 80%
after gastrectomy or gastric bypass in hu-
mans (11). It was recently shown that ghrelin
crosses the blood brain barrier, and this trans-
port occurs in both directions, from blood to
brain and from the central nervous system to
blood (12). It has also been shown that the
acyl residue is important for this transport
(12). The gene that encodes ghrelin was also
identified (5) and is located on chromosome
3 in man. This gene encodes a precursor of
117 amino acids, with an 82% homology
within species (5). In the stomach, two iso-
forms of prepro-ghrelin mRNA are produced
by the same gene by alternative splicing (5).
One encodes the ghrelin precursor while the
other encodes des-Gln14 ghrelin precursor,
which lacks glutamine at position 14 (5).
This latter peptide has 27 amino acids and is
biologically active, but is present in small
amounts. Therefore, the main active form is
ghrelin. Ghrelin is located in the submucosal
layer of the stomach fundus, in endocrine
oxyntic cells (X/A) which are near the capil-
laries and not in contact with the lumen, and
also, at lower concentrations, in the gas-
trointestinal tract (7). Both ghrelin and its
mRNA are present in the arcuate nucleus of
the hypothalamus and in the pituitary gland
(5,10). Both n-octanoyl-modified, which is
the major form, and des-acyl ghrelin were
recently identified in the rat hypothalamus.
At the pituitary level ghrelin might act in
autocrine or paracrine manner. Recently, it
has been shown that ghrelin is expressed in
lactotrophs, somatotrophs and thyrotrophs,
cells which are dependent on Pit-1 gene
expression for differentiation (8). Interest-
ingly, ghrelin is capable of modulating Pit-1
transcription. In peripheral tissues ghrelin
has a widespread distribution and has been
found in the kidney, placenta, lung, ovary,
and testis, among others, but its physiologi-
cal role in these locations remains to be
elucidated (10). Since the distribution of the
biologically active receptor (GHS-R1a) is
not the same as the peptide, it is likely that
other receptor subtypes might exist (10).
Considerable amounts of ghrelin are present
in blood and this peptide has several actions
apart from GH regulation (7,8). Ghrelin en-
hances food consumption by activation of
NPY/AGRP (agouti-related protein) neurons
in the hypothalamus, while leptin has the
opposite effect (7,8). Ghrelin is able to in-
crease GH release both in animals and in
man, and also induces prolactin, ACTH, cor-
tisol, and aldosterone secretion in vivo
(5,6,13,14). Ghrelin causes a slight increase
in glucose levels and a reduction of circulat-
ing insulin (14). The discovery of ghrelin
reinforced the concept of a third pathway of
GH regulation (2,3,7,8). However, the physi-
ological role of this potent endogenous GHRP
remains to be determined.
Mechanism of action and
physiological role of GHS and
ghrelin on GH release
GHS and ghrelin act at both hypothalam-
ic and pituitary levels to modulate GH secre-
tion (for reviews, see Refs. 3,7,8). These
peptides directly activate the GHS-R in pitu-
itary cells in vitro to stimulate GH release
(5). When GHRH is associated with GHS or
ghrelin in vitro, an additive response is ob-
served in most studies. However, when these
peptides are administered together with
GHRH in vivo, a synergistic effect on GH
release is observed, which indicates differ-
ent mechanisms of action of GHS and GHRH
and suggests a main hypothalamic site of
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action of GHS (6,14-16). Moreover, in hy-
pothalamic pituitary disconnection there is a
lack of GH release after GHRP-6 or ghrelin,
both in animals and in man (17,18). It has
been shown that an intact GHRH system is
necessary for these actions to occur. The
administration of antibodies against GHRH
decreases both GH pulsatility and GH re-
sponsiveness to ghrelin and GHS in rats
(19). GHS-induced GH release is also inhib-
ited by a GHRH antagonist (20). In the lit/lit
mouse, which has a GHRH receptor muta-
tion, GHS do not increase GH release, but
there is an enhancement of hypothalamic c-
fos expression, which is a marker of neu-
ronal activity (21). The GH response to GHS
is blunted in humans with GHRH receptor
mutations, but the ACTH- and prolactin-
releasing effects are preserved, suggesting
that they are mediated by the hypothalamus
(22). The arcuate nucleus is the main target
of ghrelin action, where ghrelin may bind
and activate the GHS-R. It has been shown
that GHS and ghrelin act centrally by in-
creasing electrical activity and c-fos expres-
sion in a subpopulation of cells in the arcuate
nucleus, some of which are GHRH-produc-
ing neurons (21). Moreover, one fourth of
these GHRH neurons express the GHS-R,
suggesting a direct effect of GHS on these
cells (19) (Figure 1).
Ghrelin also increases GHRH release
from hypothalamic tissue in vitro, but this
was not observed with GHS (23,24). It has
also been shown that GHS increase GHRH
release into the pituitary portal system in
sheep (25). GHS and ghrelin did not alter
hypothalamic somatostatin release in most
in vivo and in vitro studies (23-25). How-
ever, GHS act as functional somatostatin
antagonists (19,26). GHS cause depolariza-
tion of the somatotroph and an increase in
the number of cells secreting GH, while
somatostatin has the opposite effect (26).
A model for the action of GHS/ghrelin
has been proposed which involves: 1) a func-
tional antagonism of somatostatin; 2) activa-
tion of GHRH producing neurons in the
arcuate nucleus, leading to an increase in
GHRH release; 3) amplification of the effect
of GHRH at the somatotroph level (2). At the
pituitary level, GHS/ghrelin and GHRH bind
to different receptors, and there is evidence
of cross-talk between them (for a review, see
Ref. 7). These peptides also activate differ-
ent intracellular transduction pathways at
the somatotroph level. GHRH stimulates in-
tracellular cyclic AMP and protein kinase A
mechanisms, while GHRP-6 activates pro-
tein kinase C, via inositol triphosphate sig-
nal transduction, with an increase in intra-
cellular calcium concentrations (2,4) (Fig-
ure 1). Interestingly, it has been recently
shown in pigs that ghrelin is able to stimulate
multiple, interdependent, intracellular path-
ways at the somatotroph level, involving
protein kinase A, C and extracellular cal-
cium systems, with a broader effect than that
of most GHS, but similar to that reported for
GHRP-2 in this species (27). These data also
Figure 1. Proposed model of the interactions between GHRH and ghrelin/GHS at the
hypothalamic and pituitary level. GHRH = growth hormone-releasing hormone; GHS =
growth hormone secretagogues; PKA = protein kinase A; PKC = protein kinase C. Taken in
part from ref. 20, with permission.
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suggest the possibility of cross-talk between
these transduction pathways. However, the
physiological role of these potent stimula-
tors of GH release is not clear.
A controversial issue is whether circulat-
ing ghrelin has a role in pituitary GH secre-
tion. It is also unknown how the hypotha-
lamic peptide participates in GH modula-
tion. In the rat, ghrelin secretion occurs in a
pulsatile manner, with no correlation with
GH pulses, but in association with feeding
and sleeping cycles (28). Also, circulating
ghrelin levels were similar during the GH
peak and trough periods in the rat (29).
Ghrelin immunoneutralization did not alter
GH pulsatility, while GHRH antibodies com-
pletely blocked endogenous pulsatile GH
release (30). In humans, the administration
of a GHRH antagonist strongly inhibited 24-
h GH secretion, but failed to affect circulat-
ing ghrelin levels (31). However, in rats,
intracerebroventricular or peripheral admin-
istration of GHS-R1a antagonists attenuated
spontaneous GH secretion, basically by a
decrease in pulse amplitude and mean GH
levels (32-34). Interestingly, a missense
mutation in the GHS-R, which severely im-
paired ghrelin binding, was associated with
a case of familial short stature (35). It has
also been shown in healthy volunteers that
circulating ghrelin is related to GH pulses,
suggesting that ghrelin participates in the
pulsatile regulation of GH secretion or that
the two hormones are regulated in parallel
(36). Therefore, endogenous ghrelin might
amplify the basic pattern of GH secretion
(32-34). This peptide may also have a physi-
ological role in GH release by optimizing
somatotroph responsiveness to GHRH (37).
Nevertheless, recent studies with ghrelin
knockout animals failed to show a major
effect on GH regulation (38). In contrast to
predictions, these animals were not anorexic
dwarfs (38). However, reduced GH and IGF-
I levels were observed in transgenic models
with decreased GHS-R mRNA expression
in the arcuate nucleus (39). Also, GHS-R
knockout mice had lower body weight and
IGF-I values (40). These effects were only
moderate, which is intriguing, since these
peptides are quite potent GH stimulators. It
has been suggested that the role of ghrelin in
GH secretion might become more relevant
during states of negative energy balance (30).
However, further studies are necessary to
elucidate the physiological role of these pep-
tides in GH secretion.
Regulation of GH secretion by
GHRP-6 and ghrelin in man
GHRP-6 and ghrelin increase GH release
in a dose-dependent manner both in vivo and
in vitro in several species, including man
(1,5,6,13,16). The GH-releasing activity of
ghrelin is similar to that of GHRH in vitro
(5). However, in man, iv ghrelin administra-
tion at a dose of 1 µg/kg increases GH re-
lease in a potent manner and this response is
higher than that obtained with GHRH, hexa-
relin and GHRP-6 (13,14,41). This effect is
not specific since there is also an increase in
prolactin, ACTH, cortisol, and aldosterone
(14). Insulin values decrease and glucose
levels increase after iv administration of this
peptide (14). The latter effects and the aldo-
sterone stimulation are not seen with other
GHS. When ghrelin or GHRP-6 is adminis-
tered together with GHRH a synergistic ef-
fect is seen, but with ghrelin this is better
observed with low doses of this peptide (0.08
and 0.2 µg/kg) (14,16). It has been demon-
Figure 2. Serum growth hor-
mone (GH) concentration after
ghrelin administration (1 µg/kg,
iv ) in patients with Cushing’s
disease (N = 12) and in controls
(N = 9) (from Ref. 58, with per-
mission).
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strated that the combined administration of
GHRP-6 and GHRH is an excellent test for
the diagnosis of GH deficiency in adults.
There are no gender differences in the GH
responsiveness to GHRP-6 and ghrelin (3,
15,42), but an age-related decrease of the
response has been reported for both peptides
(3,15,42). Obese subjects have blunted GH
responses to GHRP-6 and ghrelin (43,44).
Recently, a 55% decrease in ghrelin-induced
GH release was shown in women with vis-
ceral adiposity and a body mass index of
36.2 kg/m2 (44). There is a highly reproduc-
ible response to GHS in normal subjects
studied on different occasions, different from
that observed for GHRH. Hyperglycemia,
free fatty acids and somatostatin decrease
GHRP-6 and the ghrelin-induced GH re-
sponse (45,46). Arginine was not able to
alter GH responsiveness to ghrelin (47).
The effect of cholinergic agonists and
antagonists on ghrelin-induced GH release
is controversial. Pyridostigmine failed to
modify GH responsiveness to both ghrelin
and GHRP-6 (15,48). However, atropine
blunted this response, but pirenzepine, a
muscarinic receptor antagonist, was not able
to alter GH release after ghrelin (48). These
latter compounds only blunt the GH response
to GHRP-6, while they completely abolish
the GH response to GHRH (15). Glucocorti-
coid and GH administration, which prob-
ably enhances hypothalamic somatostatin
release, only attenuates the GH response to
GHS (49,50).
In patients with Cushing’s disease, a
blunted GH response to both GHRP-6 and
ghrelin has been reported by us and by oth-
ers (51-54) (Figure 2). In these patients GHS-
and ghrelin-induced ACTH and cortisol re-
lease is enhanced (53-55), which could be
due to a direct action of these peptides on the
GHS-R in the corticotroph adenoma or, per-
haps, activation of hypothalamic arginine
vasopressin and also, to some extent, corti-
cotrophin-releasing hormone pathways (7).
Interestingly, chronic glucocorticoid admin-
istration does not interfere with GHRP-6-
induced GH release (52). This might indi-
cate, as suggested previously, that the time
of exposure to hypercortisolism determines
the GH response to these peptides. In adre-
nal insufficiency a 72-h withdrawal of glu-
cocorticoid replacement therapy does not
influence the GH responsiveness to GHRP-
6 (56). In hyperthyroidism we have observed
a decrease in GH responsiveness to GHRH
while GHRP-6-induced GH release was
maintained, which could suggest that thy-
roid hormones interfere with GHRH-releas-
ing mechanisms, with preservation of GHRP-
6-activated pathways (57). Interestingly, we
have recently shown that there is a decrease
in the GH response to ghrelin in these pa-
tients, suggesting that thyroid hormones in-
terfere with additional pathways of GH re-
lease activated by ghrelin (58). In type 1
diabetes mellitus the GH response to GHRP-
6 and hexarelin is either normal or enhanced,
demonstrating that hyperglycemia is unable
to decrease the GH release induced by these
peptides, differently than in normal subjects
(59). It has recently been shown that ghrelin-
induced GH release is decreased in anorexia
nervosa, which is an unexpected finding
because these patients have high GH levels
and enhanced responses to GHRH and GHS
(60). The possibility that GH-releasing sub-
stances, especially the orally active com-
pounds, could represent an alternative treat-
ment in GH-deficient states has received
considerable attention. However, these sub-
stances have failed to show benefit over GH
therapy, although they would be considered
more physiological since they induce en-
dogenous pulsatile GH release.
Conclusion
Ghrelin is a new hormone secreted from
the stomach to the circulation, but is also
produced in the hypothalamus and other tis-
sues, with both endocrine and paracrine ef-
fects. Its acyl modification is essential for its
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biological effects of enhancement of GH
release and stimulation of food intake. Sev-
eral questions remain to be answered con-
cerning the roles of circulating and hypotha-
lamic ghrelin in GH secretion. The available
data suggest that ghrelin might have a physi-
ological role in pulsatile GH release, but
further studies are necessary to clarify its
precise role in GH modulation.
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